| Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). | |
| | |
MedLine Citation:
|
PMID: 20706839 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE: The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route. Preliminary pharmacodynamic (PD) studies were also performed to enable comparison of the biological effects of the oral and intravenous formulations. PATIENTS AND METHODS: Oral belinostat was administered in a range of doses and schedules (once, twice or thrice daily), on either day 1 or days 1-5, of the second or a subsequent treatment cycle in 15 patients who were included in the phase-I trial of intravenous belinostat. Serial blood samples were collected for PK and PD (histone acetylation) analyses, and the results compared with corresponding analyses following intravenous administration. RESULTS: A total mean daily AUC of 2,767 ± 1,453 ng h/ml (8.7 ± 4.6 μM h) resulted from a dose of 1,000 mg/m(2) once daily (qd). There was no clear evidence of drug accumulation on twice daily dosing (bid); however, a trend towards accumulation was apparent when belinostat was given three times daily (tid). Mean half-life (T½) of a single dose of 1,000 mg/m(2) was 1.5 h (±0.3 h) and peak levels were reached in an average of 1.9 h (±0.3 h). The half-life was found to be independent of dose, but a trend towards increasing half-life following multiple dosing was observed. Histone H4 hyperacetylation in PBMCs estimated after oral dosing was comparable to that achieved after intravenous administration. CONCLUSIONS: High doses of oral belinostat, up to 1,000 mg/m(2) bid for 5 consecutive days, have been tolerated in this small study. An oral formulation could lead to enhanced drug exposure and, more importantly, prolonged effects on the intended drug target. Future trials are required to establish the optimal dose and schedule of oral administration of belinostat. |
| | |
Authors:
|
N L Steele; J A Plumb; L Vidal; J Tjørnelund; P Knoblauch; P Buhl-Jensen; R Molife; R Brown; J S de Bono; T R J Evans |
Related Documents
:
|
19641919 - Evaluation of the exposure equivalence of oral versus intravenous temozolomide. 8654189 - Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific resh... 2000829 - Relative bioavailability of deuterium-labeled monoglutamyl and hexaglutamyl folates in ... 22566669 - Bctp, a classic polymodal inhibitor of trpv1 with a reduced liability for hyperthermia,... 4063949 - Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha a in mo... 20187829 - Effects of domperidone on digital laminar microvascular blood flow in clinically normal... 15675469 - How to study boron biodistribution in liver metastases from colorectal cancer. 5492439 - Effect of trace elements on citric acid fermentation by aspergillus niger. 904969 - Effect of intermittent phototherapy on bilirubin dynamics in gunn rats. |
Publication Detail:
|
Type: Journal Article Date: 2010-08-13 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 67 ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1273-9 Citation Subset: IM |
Affiliation:
|
Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, United Kingdom, nicola.steele@ggc.scot.nhs.uk. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The influence on outcome of indications for antireflux surgery.
Next Document: High-resolution 3D non-contrast-enhanced, ECG-gated, multi-step MR angiography of the lower extremit...